Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in...
Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 Mirum...
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosu...
KOMO Biosciences, a developer of non-viral targeted insertion technologies, today announced that it has granted Syngenta, a world leader in agricultural ...
iPSCore platform delivered over 500 characterized iPSC lines during first year of collaboration iXCells Biotechnologies USA, Inc. (“iXCe...
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced it has ent...
Acadia Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the ...
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as mono...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering...
Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio establi...
Stellaromics launched Pyxa™, the first commercially available platform to deliver multiplexed 3D spatial transcriptomics in intact tissue up to 100...
Merlin CP-GEP is the only molecular test recognized by NCCN as predictive and appropriate for use in select T1 and T2 patients to support shared d...
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 14...
© 2026 Biopharma Boardroom. All Rights Reserved.
